Presentation

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat haematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumour cells.

Melflufen is in development as a new treatment for the haematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study, the phase 1/2 combination study ANCHOR and the phase 2 Study BRIDGE.

Based on the results from the HORIZON study Oncopeptides has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma.

Oncopeptides’ headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Massachusetts, and in Mountain View, California. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.